These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29452720)

  • 1. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
    Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
    Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
    Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
    Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
    Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
    Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
    Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR
    J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
    Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
    J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
    Romee R; Cooley S; Berrien-Elliott MM; Westervelt P; Verneris MR; Wagner JE; Weisdorf DJ; Blazar BR; Ustun C; DeFor TE; Vivek S; Peck L; DiPersio JF; Cashen AF; Kyllo R; Musiek A; Schaffer A; Anadkat MJ; Rosman I; Miller D; Egan JO; Jeng EK; Rock A; Wong HC; Fehniger TA; Miller JS
    Blood; 2018 Jun; 131(23):2515-2527. PubMed ID: 29463563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
    Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
    Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
    Xu W; Jones M; Liu B; Zhu X; Johnson CB; Edwards AC; Kong L; Jeng EK; Han K; Marcus WD; Rubinstein MP; Rhode PR; Wong HC
    Cancer Res; 2013 May; 73(10):3075-86. PubMed ID: 23644531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
    Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
    Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8
    Liu B; Zhu X; Kong L; Wang M; Spanoudis C; Chaturvedi P; George V; Jiao JA; You L; Egan JO; Echeverri C; Gallo VL; Xing J; Ravelo K; Prendes C; Antolinez J; Denissova J; Muniz GJ; Jeng EK; Rhode PR; Wong HC
    Mol Ther; 2021 Oct; 29(10):2949-2962. PubMed ID: 34091051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
    Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
    Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
    Margolin K; Morishima C; Velcheti V; Miller JS; Lee SM; Silk AW; Holtan SG; Lacroix AM; Fling SP; Kaiser JC; Egan JO; Jones M; Rhode PR; Rock AD; Cheever MA; Wong HC; Ernstoff MS
    Clin Cancer Res; 2018 Nov; 24(22):5552-5561. PubMed ID: 30045932
    [No Abstract]   [Full Text] [Related]  

  • 15. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
    Liu B; Kong L; Han K; Hong H; Marcus WD; Chen X; Jeng EK; Alter S; Zhu X; Rubinstein MP; Shi S; Rhode PR; Cai W; Wong HC
    J Biol Chem; 2016 Nov; 291(46):23869-23881. PubMed ID: 27650494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
    Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
    J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
    Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
    Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
    Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
    Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
    Basher F; Jeng EK; Wong H; Wu J
    Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.